{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:53:07Z","timestamp":1787003587652,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Research Foundation of Korea(NRF), funded by the Ministry of Education","award":["2021R1I1A1A01058250"],"award-info":[{"award-number":["2021R1I1A1A01058250"]}]},{"name":"National Research Foundation of Korea(NRF), funded by the Ministry of Education","award":["RS-2023-00241523"],"award-info":[{"award-number":["RS-2023-00241523"]}]},{"DOI":"10.13039\/501100024838","name":"Samsung Medical Center","doi-asserted-by":"crossref","award":["SMO122003"],"award-info":[{"award-number":["SMO122003"]}],"id":[{"id":"10.13039\/501100024838","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-69614-x","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T19:05:52Z","timestamp":1724439952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database"],"prefix":"10.1038","volume":"14","author":[{"given":"Hyo Jung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Hwa","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"key":"69614_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4837","author":"JDB Fuentes","year":"2023","unstructured":"Fuentes, J. D. B. et al. Global stage distribution of breast cancer at diagnosis: A systematic review and meta-analysis. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2023.4837 (2023).","journal-title":"JAMA Oncol."},{"issue":"7","key":"69614_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","volume":"15","author":"IE Krop","year":"2014","unstructured":"Krop, I. E. et al. Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomised, open-label, phase 3 trial. Lancet Oncol. 15(7), 689\u2013699. https:\/\/doi.org\/10.1016\/S1470-2045(14)70178-0 (2014).","journal-title":"Lancet Oncol."},{"issue":"19","key":"69614_CR3","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367(19), 1783\u20131791. https:\/\/doi.org\/10.1056\/NEJMoa1209124 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"69614_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz, G. et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. 380(7), 617\u2013628. https:\/\/doi.org\/10.1056\/NEJMoa1814017 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"69614_CR5","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/j.clbc.2019.09.001","volume":"20","author":"B Conte","year":"2020","unstructured":"Conte, B. et al. T-DM1 efficacy in patients with HER2-positive metastatic breast cancer progressing after a taxane plus pertuzumab and trastuzumab: an Italian multicenter observational study. Clin. Breast Cancer 20(2), e181\u2013e187. https:\/\/doi.org\/10.1016\/j.clbc.2019.09.001 (2020).","journal-title":"Clin. Breast Cancer"},{"issue":"4","key":"69614_CR6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","volume":"18","author":"WJ Gradishar","year":"2020","unstructured":"Gradishar, W. J. et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 18(4), 452\u2013478. https:\/\/doi.org\/10.6004\/jnccn.2020.0016 (2020).","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"20","key":"69614_CR7","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1158\/0008-5472.CAN-22-2324","volume":"82","author":"P Tarantino","year":"2022","unstructured":"Tarantino, P. & Tolaney, S. M. The dawn of the antibody\u2013drug conjugates era: How T-DM1 reinvented the future of chemotherapy for solid tumors. Cancer Res. 82(20), 3659\u20133661. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-2324 (2022).","journal-title":"Cancer Res."},{"key":"69614_CR8","unstructured":"Kadcyla (ado-trastuzumab emtansine) [package insert] (Genentech, Inc., 2013)."},{"issue":"1","key":"69614_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/abt\/tbab005","volume":"4","author":"Y Endo","year":"2021","unstructured":"Endo, Y., Mohan, N., Dokmanovic, M. & Wu, W. J. Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities: A gateway to better understanding of ADC-associated toxicities. Antibody Therap. 4(1), 55\u201359. https:\/\/doi.org\/10.1093\/abt\/tbab005 (2021).","journal-title":"Antibody Therap."},{"issue":"15","key":"69614_CR10","doi-asserted-by":"publisher","first-page":"pe12507","DOI":"10.1200\/JCO.2019.37.15_suppl.e12507","volume":"37","author":"G Buono","year":"2019","unstructured":"Buono, G. et al. Long-term toxicity profile of trastuzumab emtansine (T-DM1): A multicenter real-life study. J. Clin. Oncol. 37(15), pe12507. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.e12507 (2019).","journal-title":"J. Clin. Oncol."},{"key":"69614_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-021-00278-z","author":"MA Barbieri","year":"2022","unstructured":"Barbieri, M. A. et al. Adverse drug reactions with HER2-positive breast cancer treatment: an analysis from the Italian pharmacovigilance database. Drugs-Real World Outcomes https:\/\/doi.org\/10.1007\/s40801-021-00278-z (2022).","journal-title":"Drugs-Real World Outcomes"},{"key":"69614_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620938595","author":"M Alomar","year":"2020","unstructured":"Alomar, M. et al. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: Current status, challenges and the future. Ther. Adv. Drug Saf. https:\/\/doi.org\/10.1177\/2042098620938595 (2020).","journal-title":"Ther. Adv. Drug Saf."},{"issue":"17","key":"69614_CR13","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.7150\/jca.86746","volume":"14","author":"F Liu","year":"2023","unstructured":"Liu, F. et al. Adverse event profile differences between trastuzumab emtansine and trastuzumab deruxtecan: A real-world. Pharmacovigilance study. J. Cancer 14(17), 3275. https:\/\/doi.org\/10.7150\/jca.86746 (2023).","journal-title":"J. Cancer"},{"issue":"1","key":"69614_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-021-06469-0","volume":"194","author":"EA Perez","year":"2022","unstructured":"Perez, E. A. et al. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: A literature review. Breast Cancer Res. Treat. 194(1), 1\u201311. https:\/\/doi.org\/10.1007\/s10549-021-06469-0 (2022).","journal-title":"Breast Cancer Res. Treat."},{"key":"69614_CR15","doi-asserted-by":"publisher","first-page":"204209862091505","DOI":"10.1177\/2042098620915058","volume":"11","author":"AM Cobert","year":"2020","unstructured":"Cobert, A. M., Helms, C., Larck, C. & Moore, D. C. Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: A systematic review and meta-analysis. Therap. Adv. Drug Saf. 11, 2042098620915058. https:\/\/doi.org\/10.1177\/2042098620915058 (2020).","journal-title":"Therap. Adv. Drug Saf."},{"key":"69614_CR16","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS21-P5-18-03","author":"A Higgins","year":"2022","unstructured":"Higgins, A. et al. Abstract P5-18-03: Hepatopulmonary syndrome with long term use of ado-trastuzumab emtansine (T-DM1). Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.SABCS21-P5-18-03 (2022).","journal-title":"Cancer Res."},{"issue":"16","key":"69614_CR17","doi-asserted-by":"publisher","first-page":"e13034","DOI":"10.1200\/JCO.2023.41.16_suppl.e13034","volume":"41","author":"D Audi Blotta","year":"2023","unstructured":"Audi Blotta, D. et al. Real-world outcomes of long-term efficacy of T-DM1 after discontinuation due to limiting toxicity in patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 41(16), e13034\u2013e13034. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e13034 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"69614_CR18","first-page":"15","volume":"5","author":"M Ismail","year":"2022","unstructured":"Ismail, M. & Akram, M. U. FDA Adverse Event Reporting System (FAERS) database: A comprehensive analysis of its structure, functionality, and limitations. Sage Sci. Rev. Appl. Mach. Learn. 5(2), 15\u201329 (2022).","journal-title":"Sage Sci. Rev. Appl. Mach. Learn."},{"key":"69614_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40264-019-00897-016","volume":"43","author":"MA Mu\u00f1oz","year":"2020","unstructured":"Mu\u00f1oz, M. A. et al. Towards automating adverse event review: A prediction model for case report utility. Drug Saf. 43, 329\u2013338. https:\/\/doi.org\/10.1007\/s40264-019-00897-016 (2020).","journal-title":"Drug Saf."},{"key":"69614_CR20","unstructured":"ICH Working Group. MedDRA\u00ae data retrieval and presentation: Points to consider: ICH-endorsed guide for MedDRA users on data output (Release 3.24) (2024). Retrieved from https:\/\/files.meddra.org\/www\/Website%20Files\/PtCs\/drp_ptc_r324.html#_Toc426891619."},{"key":"69614_CR21","doi-asserted-by":"publisher","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","volume":"3","author":"PM Cutroneo","year":"2024","unstructured":"Cutroneo, P. M. et al. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front. Drug. Saf. Regul. 3, 1323057. https:\/\/doi.org\/10.3389\/fdsfr.2023.1323057 (2024).","journal-title":"Front. Drug. Saf. Regul."},{"issue":"5","key":"69614_CR22","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00228-014-1658-1","volume":"70","author":"B Grundmark","year":"2014","unstructured":"Grundmark, B., Holmberg, L., Garmo, H. & Zethelius, B. Reducing the noise in signal detection of adverse drug reactions by standardizing the background: A pilot study on analyses of proportional reporting ratios-by-therapeutic area. Eur. J. Clin. Pharmacol. 70(5), 627\u2013635. https:\/\/doi.org\/10.1007\/s00228-014-1658-1 (2014).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"69614_CR23","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s40264-014-0225-0","volume":"37","author":"KB Hoffman","year":"2014","unstructured":"Hoffman, K. B. et al. Stimulated reporting: the impact of US food and drug administration-issued alerts on the Adverse Event Reporting System (FAERS). Drug Saf. 37, 971\u2013980. https:\/\/doi.org\/10.1007\/s40264-014-0225-0 (2014).","journal-title":"Drug Saf."},{"key":"69614_CR24","unstructured":"Administration, U.S. FDA. FAERS quarterly data extract (QDE) files [cited 2023 Sep 28, 2023]. https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html."},{"key":"69614_CR25","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40265-013-0050-2","volume":"73","author":"A Ballantyne","year":"2013","unstructured":"Ballantyne, A. & Dhillon, S. Trastuzumab emtansine: First global approval. Drugs 73, 755\u2013765. https:\/\/doi.org\/10.1007\/s40265-013-0050-2 (2013).","journal-title":"Drugs"},{"key":"69614_CR26","unstructured":"Administration, U.S.FDA. FDA Adverse Event Reporting System (FAERS) Public Dashboard [cited 2023 Nov 06, 2023]. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard."},{"key":"69614_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.26","volume":"3","author":"JM Banda","year":"2016","unstructured":"Banda, J. M. et al. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci. Data 3, 160026. https:\/\/doi.org\/10.1038\/sdata.2016.26 (2016).","journal-title":"Sci. Data"},{"key":"69614_CR28","unstructured":"MedDRA\u00ae. The Medical Dictionary for Regulatory Activities [cited Sep 29, 2023]. https:\/\/www.meddra.org\/."},{"issue":"1","key":"69614_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2041-1480-5-36","volume":"5","author":"L Wang","year":"2014","unstructured":"Wang, L., Jiang, G., Li, D. & Liu, H. Standardizing adverse drug event reporting data. J. Biomed. Semant. 5(1), 1\u201313 (2014).","journal-title":"J. Biomed. Semant."},{"key":"69614_CR30","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.25818","author":"M Maciejewski","year":"2017","unstructured":"Maciejewski, M. et al. Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets. Elife https:\/\/doi.org\/10.7554\/eLife.25818 (2017).","journal-title":"Elife"},{"issue":"6","key":"69614_CR31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate, A. & Evans, S. J. W. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol. Drug Saf. 18(6), 427\u2013436. https:\/\/doi.org\/10.1002\/pds.1742 (2009).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"6","key":"69614_CR32","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/clpt.2012.50","volume":"91","author":"R Harpaz","year":"2012","unstructured":"Harpaz, R. et al. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin. Pharmacol. Therap. 91(6), 1010\u20131021. https:\/\/doi.org\/10.1038\/clpt.2012.50 (2012).","journal-title":"Clin. Pharmacol. Therap."},{"issue":"6","key":"69614_CR33","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc, J. L., Sommet, A., Bagheri, H. & Lapeyre-Mestre, M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Brit. J. Clin. Pharmacol. 72(6), 905. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04037.x (2011).","journal-title":"Brit. J. Clin. Pharmacol."},{"key":"69614_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1268672","author":"MA Barbieri","year":"2023","unstructured":"Barbieri, M. A. et al. Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: An analysis from the FDA Adverse Event Reporting System. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2023.1268672 (2023).","journal-title":"Front. Oncol."},{"key":"69614_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n, G. N. et al. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med. Res. 22, 57\u201369. https:\/\/doi.org\/10.1177\/0962280211403604 (2013).","journal-title":"Stat Methods Med. Res."},{"issue":"1","key":"69614_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12859-018-2137-y","volume":"19","author":"Y Noguchi","year":"2018","unstructured":"Noguchi, Y. et al. A simple method for exploring adverse drug events in patients with different primary diseases using spontaneous reporting system. BMC Bioinform. 19(1), 1\u20137. https:\/\/doi.org\/10.1186\/s12859-018-2137-y (2018).","journal-title":"BMC Bioinform."},{"issue":"7","key":"69614_CR37","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T. et al. Data mining of the public version of the FDA Adverse Event Reporting System. Int. J. Med. Sci. 10(7), 796. https:\/\/doi.org\/10.7150\/ijms.6048 (2013).","journal-title":"Int. J. Med. Sci."},{"issue":"1","key":"69614_CR38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/cpt.2920","volume":"114","author":"S Xia","year":"2023","unstructured":"Xia, S. et al. Tumor lysis syndrome associated with monoclonal antibodies in patients with multiple myeloma: A pharmacovigilance study based on the FAERS database. Clin. Pharmacol. Therap. 114(1), 211\u2013219. https:\/\/doi.org\/10.1002\/cpt.2920 (2023).","journal-title":"Clin. Pharmacol. Therap."},{"issue":"11","key":"69614_CR39","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1248\/bpb.b19-00156","volume":"42","author":"G Ando","year":"2019","unstructured":"Ando, G. et al. Evaluation of the expression time of ganciclovir-induced adverse events using JADER and FAERS. Biol. Pharm. Bull. 42(11), 1799\u20131804. https:\/\/doi.org\/10.1248\/bpb.b19-00156 (2019).","journal-title":"Biol. Pharm. Bull."},{"key":"69614_CR40","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2165\/11599740-000000000-00000","volume":"35","author":"VR Cornelius","year":"2012","unstructured":"Cornelius, V. R., Sauzet, O. & Evans, S. J. A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data. Drug Saf. 35, 599\u2013610. https:\/\/doi.org\/10.2165\/11599740-000000000-00000 (2012).","journal-title":"Drug Saf."},{"issue":"1","key":"69614_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-14-17","volume":"14","author":"F Leroy","year":"2014","unstructured":"Leroy, F. et al. Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases. BMC Med. Res. Methodol. 14(1), 1\u201311. https:\/\/doi.org\/10.1186\/1471-2288-14-17 (2014).","journal-title":"BMC Med. Res. Methodol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69614-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69614-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69614-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T19:20:30Z","timestamp":1724440830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69614-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["69614"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-69614-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YHP has served as a consultant or advisor for the following pharmaceutical companies: AstraZeneca, Pfizer, Lilly, MSD, Eisai, Roche, Daiichi-Sankyo, MENARINI, Bixink, Everest, Gilead, and Novartis, Inc. and has received grants and research funding from the following organizations: MSD, Pfizer, AstraZeneca, Novartis, Genome Insight, NGenBio, and Roche. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19587"}}